Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Ascentage Pharma Group International Unsponsored ADR ( (AAPG) ) just unveiled an update.
Ascentage Pharma Group International is a global, commercial-stage biopharmaceutical company specializing in innovative oncology therapies, including apoptotic pathway inhibitors, next-generation kinase inhibitors and protein degraders. Its lead products, Olverembatinib and Lisaftoclax, are approved in China for chronic myeloid leukemia and chronic lymphocytic leukemia/small lymphocytic lymphoma respectively and are supported by multiple ongoing global Phase III trials aimed at broadening their use in CML, Ph+ ALL, SDH-deficient GIST, AML and higher-risk MDS.
On May 12, 2026, Ascentage Pharma announced that its management will participate in three investor conferences: the B. Riley Commercial/Late-Stage Oncology Best Ideas Summit on May 18, the Stifel 2026 Virtual Targeted Oncology Forum on May 19 and the Jefferies Global Healthcare Conference in New York on June 3. By engaging with investors through one-on-one meetings, a fireside chat and a formal presentation, the company is seeking to highlight its expanding oncology portfolio and late-stage clinical programs, potentially strengthening investor awareness and capital markets positioning as it advances multiple registrational studies.
The most recent analyst rating on (AAPG) stock is a Buy with a $40.00 price target. To see the full list of analyst forecasts on Ascentage Pharma Group International Unsponsored ADR stock, see the AAPG Stock Forecast page.
Spark’s Take on AAPG Stock
According to Spark, TipRanks’ AI Analyst, AAPG is a Underperform.
The score is primarily constrained by weak financial performance driven by persistent and worsening losses and significant cash burn, despite strong revenue growth and high gross margins. Technicals also reflect a weak trend with negative momentum. Valuation is further pressured by a negative P/E and no dividend yield data.
To see Spark’s full report on AAPG stock, click here.
More about Ascentage Pharma Group International Unsponsored ADR
Ascentage Pharma Group International is a global, commercial-stage, integrated biopharmaceutical company focused on novel, differentiated therapies for cancer and other diseases with high unmet medical need. Its pipeline includes apoptotic pathway inhibitors, next-generation kinase inhibitors and protein degraders, supported by global IP and partnerships with major pharma and leading research institutions.
The company’s first approved product, Olverembatinib, is a third-generation BCR-ABL1 inhibitor approved in China for multiple forms of CML and covered by the National Reimbursement Drug List, while a suite of global Phase III trials, including the POLARIS program, is underway to expand its indications. Ascentage’s second approved product, Lisaftoclax, a Bcl-2 inhibitor for hematologic malignancies, is approved in China for relapsed or previously treated CLL/SLL and is being tested in several global Phase III GLORA studies spanning CLL/SLL, AML and higher-risk MDS.
Average Trading Volume: 3,127
Technical Sentiment Signal: Sell
Current Market Cap: $2.02B
Find detailed analytics on AAPG stock on TipRanks’ Stock Analysis page.